FTY720, a novel immunomodulator in de novo kidney transplant patients: Pharmacokinetics and exposure-response relationship

Journal of Clinical Pharmacology

Volumn 45, Issue 11, 2005, Pages 1268-1278

  Skerjanec, Andrej ^a   Tedesco, Helio ^b   Neumayer, Hans H ^c   Cole, Edward ^d   Budde, Klemens ^c   Hsu, Chyi Hung ^a   Schmouder, Robert ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Concentration efficacy relationship; Kidney transplantation; Population methods

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; FINGOLIMOD; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; BODY WEIGHT; BRADYCARDIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEADY STATE; TREATMENT OUTCOME;

ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 27244457788     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005279799     Document Type: Article

References (14)

1. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant. 2002;2:898-903.
2. Kahan BD. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Ther Drug Monit. 2002;24:47-52.
3. Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation. 2003;76:1079-1084.
4. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983;11:303-319.
5. Schmouder R, Dannecker R, Choudhury S, Barilla D, Sablinski T. FTY720 metabolism in humans [abstract 1338]. In: 19th Annual Meeting of the American Society of Transplantation; 2001; Chicago, 111.
6. Li H, Meno-Tetang GM, Chiba K, Arima N, Reining P, Jusko WJ. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J Pharmacol Exp Ther. 2002;301:519-526.
7. Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm. 1991;19:333-353.
8. Aarons L, Balant LP, Mentre F, et al. Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol. 1994;46:389-391.
9. Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation. 2001;72:1056-1061.
10. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72:660-669.
11. Parke J, Charles BG. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit. 1998;20:284-293.
12. Troncoso P, Kahan BD. Preclinical evaluation of a new immunosuppressive agent, FTY720. Clin Biochem. 1998;31:369-373.
13. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-21457.
14. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13:1073-1083.